The lipid flippase SLC47A1 blocks metabolic vulnerability to ferroptosis

Area of Science:

• Cellular Biology
• Biochemistry
• Oncology

Background:

• Ferroptosis, a regulated necrosis driven by lipid peroxidation, is crucial in cancer therapy.
• The precise lipid remodeling mechanisms governing ferroptosis sensitivity are not fully understood.

Purpose of the Study:

• To investigate the role of lipid transporters in ferroptosis regulation.
• To identify novel molecular targets for enhancing ferroptosis-based cancer treatments.

Main Methods:

• Screening of phospholipid transporters for differential expression during ferroptosis.
• Lipidomics and functional assays to assess the impact of SLC47A1 on ferroptosis.
• Identification of transcription factors regulating SLC47A1.
• In vivo studies using ferroptosis inducers and pathway blockade.

Main Results:

• Solute carrier family 47 member 1 (SLC47A1) was identified as a key regulator of lipid remodeling and survival in ferroptosis.
• SLC47A1 upregulation confers resistance to ferroptosis by modulating polyunsaturated fatty acid cholesterol ester production.
• Peroxisome proliferator activated receptor alpha (PPARA) was identified as a transcriptional activator of SLC47A1.
• Blocking the PPARA-SLC47A1 pathway potentiated the anticancer effects of ferroptosis inducers in preclinical models.

Conclusions:

• SLC47A1 plays a critical role in lipid metabolism and ferroptosis resistance.
• The PPARA-SLC47A1 axis represents a novel therapeutic target for overcoming resistance to ferroptosis inducers.
• Targeting lipid transporters offers a promising strategy for enhancing cancer therapy.